This protocol applies to patients with Loeys-Dietz syndrome who have aortic dilation or aneurysm involving the aortic root or the ascending thoracic aorta — a population with distinct vascular and systemic features that shape the choice of management.
Loeys-Dietz syndrome is characterized by aortic and branch vessel aneurysms and dissections, arterial tortuosity, and skeletal features similar to those seen in Marfan syndrome but with unique craniofacial and cutaneous features. When aortic root or ascending thoracic aortic dilation or aneurysm is present in this context, a specific pharmacological strategy is indicated.
Pharmacological therapy targeting cardiovascular risk — drawn from specific established drug classes — forms the basis of medical management in this setting, optimized to the maximum dose each patient can tolerate.
Loeys-Dietz syndrome is characterized by aortic and branch vessel aneurysms and dissections, arterial tortuosity, and skeletal features similar to those seen in Marfan syndrome but with unique craniofacial and cutaneous features.
In patients with Loeys-Dietz syndrome, treatment with a beta blocker or an ARB (unless contraindicated), or both, in maximally tolerated doses, is reasonable.
DOI: 10.1161/CIR.0000000000001106 View source ↗